Compare Glenmark Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUN PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUN PHARMA GLENMARK PHARMA/
SUN PHARMA
 
P/E (TTM) x 11.8 21.7 54.5% View Chart
P/BV x 1.5 2.3 65.4% View Chart
Dividend Yield % 0.7 0.7 96.3%  

Financials

 GLENMARK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
SUN PHARMA
Mar-19
GLENMARK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs712679 104.8%   
Low Rs484375 128.8%   
Sales per share (Unadj.) Rs349.6121.1 288.6%  
Earnings per share (Unadj.) Rs32.813.4 245.1%  
Cash flow per share (Unadj.) Rs44.320.7 214.3%  
Dividends per share (Unadj.) Rs2.002.75 72.7%  
Dividend yield (eoy) %0.30.5 64.1%  
Book value per share (Unadj.) Rs198.6172.6 115.1%  
Shares outstanding (eoy) m282.172,399.26 11.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.4 39.3%   
Avg P/E ratio x18.239.4 46.3%  
P/CF ratio (eoy) x13.525.5 52.9%  
Price / Book Value ratio x3.03.1 98.5%  
Dividend payout %6.120.6 29.7%   
Avg Mkt Cap Rs m168,6251,264,650 13.3%   
No. of employees `00012.017.5 68.8%   
Total wages/salary Rs m20,56159,671 34.5%   
Avg. sales/employee Rs Th8,196.016,608.1 49.3%   
Avg. wages/employee Rs Th1,708.13,409.6 50.1%   
Avg. net profit/employee Rs Th768.51,833.8 41.9%   
INCOME DATA
Net Sales Rs m98,655290,659 33.9%  
Other income Rs m2,08110,255 20.3%   
Total revenues Rs m100,736300,914 33.5%   
Gross profit Rs m15,85863,076 25.1%  
Depreciation Rs m3,25917,533 18.6%   
Interest Rs m3,3465,553 60.3%   
Profit before tax Rs m11,33550,246 22.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-12,144 -13.8%   
Tax Rs m3,7566,009 62.5%   
Profit after tax Rs m9,25032,093 28.8%  
Gross profit margin %16.121.7 74.1%  
Effective tax rate %33.112.0 277.1%   
Net profit margin %9.411.0 84.9%  
BALANCE SHEET DATA
Current assets Rs m66,968310,692 21.6%   
Current liabilities Rs m40,211173,396 23.2%   
Net working cap to sales %27.147.2 57.4%  
Current ratio x1.71.8 92.9%  
Inventory Days Days8399 84.1%  
Debtors Days Days81112 72.8%  
Net fixed assets Rs m33,322232,477 14.3%   
Share capital Rs m2822,399 11.8%   
"Free" reserves Rs m55,770411,691 13.5%   
Net worth Rs m56,052414,091 13.5%   
Long term debt Rs m35,73815,226 234.7%   
Total assets Rs m132,888646,938 20.5%  
Interest coverage x4.410.0 43.7%   
Debt to equity ratio x0.60 1,734.0%  
Sales to assets ratio x0.70.4 165.2%   
Return on assets %9.55.8 162.9%  
Return on equity %16.57.8 212.9%  
Return on capital %17.810.2 175.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99866,025 95.4%   
Fx outflow Rs m22,85938,610 59.2%   
Net fx Rs m40,14027,415 146.4%   
CASH FLOW
From Operations Rs m13,24221,965 60.3%  
From Investments Rs m-6,990-6,813 102.6%  
From Financial Activity Rs m-7,387-27,305 27.1%  
Net Cashflow Rs m-2,971-8,442 35.2%  

Share Holding

Indian Promoters % 48.3 63.7 75.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.1 134.5%  
FIIs % 34.4 23.0 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   56,727 133,026 42.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   AUROBINDO PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 807 Points on Coronavirus Fears; Metal and Automobile Stocks Fall(Closing)

Indian share markets fell sharply today, tracking a global selloff as coronavirus cases spiked outside China.

Related Views on News

WOCKHARDT Plunges by 5%; BSE HEALTHCARE Index Down 1.8% (Market Updates)

Feb 24, 2020 | Updated on Feb 24, 2020

WOCKHARDT share price has plunged by 5% and its current market price is Rs 359. The BSE HEALTHCARE is down by 1.8%. The top gainers in the BSE HEALTHCARE Index are SHILPA MEDICARE (up 5.0%) and SUVEN LIFESCIENCES (up 4.9%). The top losers are WOCKHARDT (down 5.4%) and CAPLIN POINT (down 9.1%).

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 24, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - DR. REDDYS LAB COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS